Results 131 to 140 of about 39,781 (168)

Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study. [PDF]

Lancet HIV
Hwang YJ, Lesko CR, Brown TT, Alexander GC, Althoff KN, Zalla LC, Pytell JD, Falade-Nwulia O, Tseng E, Moore RD, Marconi VC, Koethe JR, Silverberg MJ, Horberg MA, Lang R, Sterling TR, Fojo AT, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS.   +17 more
europepmc   +1 more source

Time to Antiretroviral Therapy Initiation After HIV Diagnosis in the Integrase Strand Transfer Inhibitor Era - Nanjing City, Jiangsu Province, China, 2021-2024. [PDF]

China CDC Wkly
Ma C, Yang J, Liu A, Qian Z, Liu Z, Ge Y, Xu Y, Zhu Z, Wei H, Peng Z, Yin G, Hu Z.   +11 more
europepmc   +1 more source

Changes in weight and glycemia after initiation of integrase strand transfer inhibitors among people with HIV and diabetes. [PDF]

AIDS
Hwang YJ, Lesko CR, Brown TT, Alexander GC, Althoff KN, Falade-Nwulia O, Moore RD, Zalla LC, Tseng E, Koethe JR, Rebeiro PF, Marconi VC, Silverberg MJ, Horberg MA, Davy-Mendez T, Lang R, Kassaye SG, Fojo AT, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA).   +18 more
europepmc   +1 more source

Five-Year Immune Recovery After ART Initiation Among PLWH Aged ≥15 Years with Baseline Immunosuppression - China, 2013-2024. [PDF]

China CDC Wkly
Geng Y, Jia H, Guan Y, Ren R, Zhao D, Gan X, Huang L, Liu N, Peng Z, Zhao Y.   +9 more
europepmc   +1 more source

Evolution and forecasting of antiretroviral therapy utilisation in British Columbia: a population-level analysis of provincial drug treatment programme data, 2014-2024. [PDF]

BMJ Open
Lima VD, Mokhtari Jazi A, Montaner JSG.
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

Integrase inhibitor-based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection. [PDF]

Front Med (Lausanne)
Karaca B, Şener A, Kaptan F, Ece D, Örmen B, Caner A.   +5 more
europepmc   +1 more source

Long‑Term Effectiveness and Safety of Doravirine‑Based Antiretroviral Regimens in Virologically Suppressed People with HIV: The French Dat'AIDS Cohort. [PDF]

Infect Dis Ther
Allavena C, Fleming SP, Deschanvres C, Mariot P, Chaillon A, Chéret A, Dellamonica P, Cabié A, Hocqueloux L, Dat’AIDS Study Group.   +9 more
europepmc   +1 more source

Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. [PDF]

Lancet HIV
Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ.   +27 more
europepmc   +1 more source